Annovis Bio, Inc. (ANVS): Nasdaq/NYSE listing notice — Annovis Bio receives NYSE delisting notice, market cap ~$37.9M, equity $9.3M; CFO Fricker departs

Annovis Bio, Inc.

NYSE notice: 30-day avg mkt cap ~$37.9M, equity $9.3M at Dec 31, 2024, both below $50M thresholds.
Company has 45 days to submit compliance plan; NYSE may grant up to 18-month cure period; symbol gets '.BC' indicator.
No immediate impact on stock listing, business operations, or SEC reporting obligations.
Interim CFO William Fricker departs March 27 by mutual agreement; no dispute over accounting.
CEO Maria Maccecchini assumes interim principal financial officer role.

item 3.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

William Fricker

Interim Chief Financial Officer

ANVS · Annovis Bio, Inc.

Effective: 2025-03-27
Successor: Maria Maccecchini
Filed: March 27, 2025, 7:59 PM ET

On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.

Appointed (interim)

Maria Maccecchini

Principal Financial Officer on an interim basis

ANVS · Annovis Bio, Inc.

Effective: 2025-03-27
Filed: March 27, 2025, 7:59 PM ET

Maria Maccecchini will continue to serve as principal financial officer on an interim basis.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Annovis Bio, Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B).

Exchange: nyse
Notice: deficiency notice
Deficiency: market value
Rules: 802.01B

Exact text from the filing

March 26, 2025, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. As set forth in the Notice, as of March 25, 2025, the 30 trading-day average global market capitalization of the Company was

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William Fricker departed as Interim Chief Financial Officer at Annovis Bio, Inc..

Action: will no longer serve
Role: Interim Chief Financial Officer

Exact text from the filing

On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Maria Maccecchini was appointed as Principal Financial Officer on an interim basis at Annovis Bio, Inc..

Action: appointed
Role: Principal Financial Officer on an interim basis

Exact text from the filing

Maria Maccecchini will continue to serve as principal financial officer on an interim basis.

View on SEC.gov

Browse all listing & compliance notices →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-028803

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.